Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Persistent complement activation on tumor cells in breast cancer.

F Niculescu1, H G Rus, M Retegan

  • 1Medical Clinic No. 1, Cluj-Napoca, Romania.

The American Journal of Pathology
|May 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the origin of low-valent uranium oxidation state.

Nature communications·2024
Same author

Serum zinc and copper in hyperlipoproteinemia.

Biological trace element research·2013
Same author

Comparative theoretical studies of the phosphomonoester hydrolysis mechanism by purple acid phosphatases.

The journal of physical chemistry. A·2010
Same author

Vasospastic angina caused by 5-fluorouracil. A case report.

Romanian journal of internal medicine = Revue roumaine de medecine interne·2004
Same author

Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells.

Immunologic research·2001
Same author

C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway.

Journal of immunology (Baltimore, Md. : 1950)·2001

The study found that C5b-9 complement complex deposits are present in breast cancer tissues but absent in benign tumors. These deposits indicate complement activation, suggesting a role in breast cancer development.

Area of Science:

  • Immunology
  • Oncology
  • Pathology

Background:

  • The complement system, a part of innate immunity, plays a role in various physiological and pathological processes.
  • Aberrant complement activation has been implicated in the pathogenesis of several diseases, including cancer.

Purpose of the Study:

  • To investigate the presence and localization of complement components and associated proteins in breast cancer tissues.
  • To determine if complement activation, specifically via the C5b-9 complex, is associated with breast carcinoma.

Main Methods:

  • Immunohistochemistry using the streptavidin-biotin-peroxidase technique was employed.
  • Antibodies against C5b-9, IgG, C3, C4, S-protein/vitronectin, fibronectin, and macrophages were used.
  • Seventeen breast carcinoma and six benign breast tumor samples were analyzed.

Related Experiment Videos

Main Results:

  • C5b-9 deposits were consistently found on tumor cells, cell remnants, and necrotic areas in all carcinoma samples across TNM stages.
  • C5b-9 deposits were absent in all benign breast tumor samples.
  • Chemotherapy and radiation therapy intensified C5b-9 deposition.
  • IgG, C3, and C4 deposits were specific to carcinoma samples.
  • S-protein/vitronectin and fibronectin showed varying deposition patterns in the tumor microenvironment.

Conclusions:

  • The presence of C5b-9 deposits in breast cancer tissues indicates complement activation.
  • Complement activation, evidenced by C5b-9, appears to be a pathogenetic factor in breast cancer.
  • C5b-9 deposition is a potential biomarker distinguishing malignant from benign breast lesions.